Literature DB >> 25308083

Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir.

Yohei Fujii1, Yoshihito Uchida, Satoshi Mochida.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25308083     DOI： 10.1002/hep.27559

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  12 in total

1.  New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection.

Authors:  A Kardashian Ara; J Pockros Paul
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-07

2.  Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir.

Authors:  Takayoshi Suga; Ken Sato; Yuichi Yamazaki; Tatsuya Ohyama; Norio Horiguchi; Satoru Kakizaki; Motoyasu Kusano; Masanobu Yamada
Journal:  World J Clin Cases       Date:  2015-12-16       Impact factor: 1.337

3.  Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.

Authors:  Etsuko Iio; Noritomo Shimada; Hiroshi Abe; Masanori Atsukawa; Kai Yoshizawa; Koichi Takaguchi; Yuichiro Eguchi; Hideyuki Nomura; Tomoyuki Kuramitsu; Jong-Hon Kang; Takeshi Matsui; Noboru Hirashima; Akihito Tsubota; Atsunori Kusakabe; Izumi Hasegawa; Tomokatsu Miyaki; Noboru Shinkai; Kei Fujiwara; Shunsuke Nojiri; Yasuhito Tanaka
Journal:  J Gastroenterol       Date:  2016-05-28       Impact factor: 6.772

Review 4.  APASL consensus statements and recommendation on treatment of hepatitis C.

Authors:  Masao Omata; Tatsuo Kanda; Lai Wei; Ming-Lung Yu; Wang-Long Chuang; Alaaeldin Ibrahim; Cosmas Rinaldi Adithya Lesmana; Jose Sollano; Manoj Kumar; Ankur Jindal; Barjesh Chander Sharma; Saeed S Hamid; A Kadir Dokmeci; Geofferey W McCaughan; Jafri Wasim; Darrell H G Crawford; Jia-Horng Kao; Osamu Yokosuka; George K K Lau; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-04-29       Impact factor: 6.047

5.  Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.

Authors:  Jung Hwan Yu; Jung Il Lee; Kwan Sik Lee; Ja Kyung Kim
Journal:  Virol J       Date:  2017-08-24       Impact factor: 4.099

6.  Successful Treatment for Chronic Hepatitis C-Autoimmune Hepatitis Overlap Syndrome due to Daclatasvir and Asunaprevir.

Authors:  Ayumi Sugiura; Shuichi Wada; Hiromitsu Mori; Takefumi Kimura; Yoshiaki Matsuda; Naoki Tanaka; Eiji Tanaka; Kendo Kiyosawa
Journal:  Case Rep Gastroenterol       Date:  2017-05-17

7.  Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions.

Authors:  Yuichi Miyashima; Yuichi Honma; Koichiro Miyagawa; Shinji Oe; Michio Senju; Michihiko Shibata; Masaaki Hiura; Shintaro Abe; Masaru Harada
Journal:  Intern Med       Date:  2016-12-15       Impact factor: 1.271

8.  Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world.

Authors:  Jae Young Oh; Byung Seok Kim; Chang Hyeong Lee; Jeong Eun Song; Heon Ju Lee; Jung Gil Park; Jae Seok Hwang; Woo Jin Chung; Byoung Kuk Jang; Young Oh Kweon; Won Young Tak; Soo Young Park; Se Young Jang; Jeong Ill Suh; Sang Gyu Kwak
Journal:  Korean J Intern Med       Date:  2018-05-25       Impact factor: 2.884

Review 9.  Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature.

Authors:  Philip Sarges; Joshua M Steinberg; James H Lewis
Journal:  Drug Saf       Date:  2016-09       Impact factor: 5.228

10.  Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.

Authors:  Yoshihito Uchida; Kayoko Naiki; Jun-Ichi Kouyama; Kayoko Sugawara; Masamitsu Nakao; Daisuke Motoya; Mie Inao; Nobuaki Nakayama; Yukinori Imai; Tomoaki Tomiya; Satoshi Mochida
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.